<li>ampicillin<p>lansoprazole will decrease the level or effect of ampicillin by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>axitinib<p>lansoprazole increases levels of axitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>bosutinib<p>lansoprazole decreases levels of bosutinib by Other (see comment). Use Caution/Monitor. 
Comment: PPIs may decrease bosutinib concentration by ~45%; bosutinib displays pH-dependent solubility.</p></li><li>budesonide<p>lansoprazole decreases effects of budesonide by increasing gastric pH. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Enteric-coated budesonide dissolves at pH &gt;5.5. Also, dissolution of extended-release budesonide tablets is pH dependent. Coadministration with drugs that increase gastric pH may cause these budesonide products to prematurely dissolve, and possibly affect release properties and absorption of the drug in the duodenum.</p></li><li>carbamazepine<p>carbamazepine will decrease the level or effect of lansoprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>carbamazepine will decrease the level or effect of lansoprazole by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.</p></li><li>carbonyl iron<p>lansoprazole will decrease the level or effect of carbonyl iron by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>clarithromycin<p>clarithromycin will increase the level or effect of lansoprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>clobazam<p>lansoprazole will increase the level or effect of clobazam by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. Dosage adjustment may be required; CYP2C19 inhibitors may result in increased exposure to N-desmethylclobazam (active metabolite).</p></li><li>clopidogrel<p>lansoprazole decreases effects of clopidogrel by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. Mean AUC of clopidogrel active metabolite was reduced by ~14% when lansoprazole was coadministered compared to administration of clopidogrel alone in healthy subjects who were CYP2C19 extensive metabolizers. Clopidogrel efficacy may be reduced by drugs that inhibit CYP2C19. Inhibition of platelet aggregation by clopidogrel is entirely due to the active clopidogrel metabolite. Clopidogrel is metabolized in part by CYP2C19.</p></li><li>crizotinib<p>lansoprazole decreases levels of crizotinib by increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor. Drugs that elevate the gastric pH may decrease the solubility of crizotinib and subsequently reduce its bioavailability. However, no formal studies have been conducted. .</p></li><li>cyclosporine<p>cyclosporine, lansoprazole.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: When used for prolonged periods of time PPIs may cause hypomagnesemia and the risk is further increased when used concomitantly with drugs that also have the same effects.<span><br><br></span>lansoprazole, cyclosporine.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: When used for prolonged periods of time PPIs may cause hypomagnesemia and the risk is further increased when used concomitantly with drugs that also have the same effects.</p></li><li>dabrafenib<p>lansoprazole will decrease the level or effect of dabrafenib by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor. Drugs that alter upper GI tract pH (eg, PPIs, H2-blockers, antacids) may decrease dabrafenib solubility and reduce its bioavailability<span><br><br></span>dabrafenib will decrease the level or effect of lansoprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely.</p></li><li>daclatasvir<p>daclatasvir will increase the level or effect of lansoprazole by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>dextroamphetamine<p>lansoprazole, dextroamphetamine. Other (see comment). Use Caution/Monitor. 
Comment: Reduced gastric acidity caused by proton pump inhibitors decreases time to Tmax for amphetamine and dextroamphetamine. AUC was unaffected. .</p></li><li>digoxin<p>lansoprazole increases toxicity of digoxin by Other (see comment). Use Caution/Monitor. 
Comment: Prolonged use of PPIs may cause hypomagnesemia and increase risk for digoxin toxicity.</p></li><li>eliglustat<p>eliglustat increases levels of lansoprazole by P-glycoprotein (MDR1) efflux transporter. Modify Therapy/Monitor Closely. Monitor therapeutic drug concentrations, as indicated, or consider reducing the dosage of the P-gp substrate and titrate to clinical effect.</p></li><li>ferric gluconate<p>lansoprazole will decrease the level or effect of ferric gluconate by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>ferrous fumarate<p>lansoprazole will decrease the level or effect of ferrous fumarate by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>ferrous gluconate<p>lansoprazole will decrease the level or effect of ferrous gluconate by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>ferrous sulfate<p>lansoprazole will decrease the level or effect of ferrous sulfate by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>flibanserin<p>lansoprazole will increase the level or effect of flibanserin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Increased flibanserin adverse effects may occur if coadministered with multiple weak CYP3A4 inhibitors.</p></li><li>fluvoxamine<p>fluvoxamine will increase the level or effect of lansoprazole by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.</p></li><li>fosamprenavir<p>lansoprazole will decrease the level or effect of fosamprenavir by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>gefitinib<p>lansoprazole decreases levels of gefitinib by increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor. Avoid coadministration of gefitinib with PPIs if possible. If treatment with a PPI is required, separate gefitinib and PPI doses by 12 hr.</p></li><li>iloperidone<p>iloperidone increases levels of lansoprazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Iloperidone is a time-dependent CYP3A inhibitor and may lead to increased plasma levels of drugs predominantly eliminated by CYP3A4.</p></li><li>iron dextran complex<p>lansoprazole will decrease the level or effect of iron dextran complex by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>iron sucrose<p>lansoprazole will decrease the level or effect of iron sucrose by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>isoniazid<p>isoniazid will increase the level or effect of lansoprazole by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.</p></li><li>itraconazole<p>itraconazole will increase the level or effect of lansoprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>ketoconazole<p>ketoconazole will increase the level or effect of lansoprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>ledipasvir/sofosbuvir<p>lansoprazole decreases levels of ledipasvir/sofosbuvir by Other (see comment). Use Caution/Monitor. 
Comment: Ledipasvir solubility decreases as pH increases; drugs that increase gastric pH are expected to decrease levels of ledipasvir; proton-pump inhibitor doses comparable to omeprazole &lt;20 mg can be administered simultaneously with ledipasvir/sofosbuvir under fasted conditions.</p></li><li>lomitapide<p>lansoprazole increases levels of lomitapide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Lomitapide dose should not exceed 30 mg/day.</p></li><li>lumacaftor/ivacaftor<p>lumacaftor/ivacaftor, lansoprazole. affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. In vitro studies suggest that lumacaftor may induce and ivacaftor may inhibit CYP2C19 substrates. .<span><br><br></span>lumacaftor/ivacaftor will decrease the level or effect of lansoprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Lumacaftor/ivacaftor is a strong CYP3A4 inhibitor and also has the potential to induce CYP2C19 and both induce and inhibitor P-gp.</p></li><li>methotrexate<p>lansoprazole increases levels of methotrexate by decreasing renal clearance. Use Caution/Monitor. Increased risk of toxicity with higher doses.</p></li><li>mitotane<p>mitotane decreases levels of lansoprazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Mitotane is a strong inducer of cytochrome P-4503A4; monitor when coadministered with CYP3A4 substrates for possible dosage adjustments.</p></li><li>mycophenolate<p>lansoprazole will decrease the level or effect of mycophenolate by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor. Potential interaction applies to mycophenolate mofetil. Enteric coated mycophenolate sodium formulation is less sensitive to this interaction. Clinical significance unclear.</p></li><li>nefazodone<p>nefazodone will increase the level or effect of lansoprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>ombitasvir/paritaprevir/ritonavir<p>ombitasvir/paritaprevir/ritonavir will decrease the level or effect of lansoprazole by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Paritaprevir and ritonavir inhibit P-gp. Caution if coadministered with P-gp substrates.</p></li><li>polysaccharide iron<p>lansoprazole will decrease the level or effect of polysaccharide iron by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>posaconazole<p>lansoprazole will decrease the level or effect of posaconazole by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>rose hips<p>lansoprazole will decrease the level or effect of rose hips by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>saquinavir<p>lansoprazole increases levels of saquinavir by unknown mechanism. Use Caution/Monitor. Potential for increased toxicity. .</p></li><li>secobarbital<p>secobarbital will decrease the level or effect of lansoprazole by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.<span><br><br></span>secobarbital will decrease the level or effect of lansoprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>st john's wort<p>st john's wort will decrease the level or effect of lansoprazole by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.<span><br><br></span>st john's wort will decrease the level or effect of lansoprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>sulpiride<p>lansoprazole will decrease the level or effect of sulpiride by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>tacrolimus<p>lansoprazole will increase the level or effect of tacrolimus by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. Concomitant administration may increase tacrolimus whole blood concentrations, particularly in intermediate or poor metabolizers of CYP2C19</p></li><li>tolbutamide<p>lansoprazole will increase the level or effect of tolbutamide by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>vismodegib<p>lansoprazole will decrease the level or effect of vismodegib by  Other (see comment). Use Caution/Monitor. Drugs that increase gastric pH alter vismodegib solubility and therefore reduce bioavailability; effect on efficacy unknown</p></li>